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Abstract
Background: Recruitment to clinical trials is difficult with many trials failing to recruit to target and within time.
Embedding trials of recruitment interventions within host trials may provide a successful way to improve this. There
are no guidelines for reporting such embedded methodology trials. As part of the Medical Research Council funded
Systematic Techniques for Assisting Recruitment to Trials (MRC START) programme designed to test interventions to
improve recruitment to trials, we developed guidelines for reporting embedded trials.
Methods: We followed a three-phase guideline development process: (1) pre-meeting literature review to generate
items for the reporting guidelines; (2) face-to-face consensus meetings to draft the reporting guidelines; and (3)
post-meeting feedback review, and pilot testing, followed by finalisation of the reporting guidelines.
Results: We developed a reporting checklist based on the Consolidated Standards for Reporting Trials (CONSORT)
statement 2010. Embedded trials evaluating recruitment interventions should follow the CONSORT statement 2010
and report all items listed as essential. We used a number of examples to illustrate key issues that arise in
embedded trials and how best to report them, including (a) how to deal with description of the host trial; (b) the
importance of describing items that may differ in the host and embedded trials (such as the setting and the
eligible population); and (c) the importance of identifying clearly the point at which the recruitment interventions
were embedded in the host trial.
Conclusions: Implementation of these guidelines will improve the quality of reports of embedded recruitment
trials while advancing the science, design and conduct of embedded trials as a whole.
Keywords: Embedded randomised controlled trial, Recruitment, Primary care, Reporting guidelines, Methodology
Background
Randomised controlled trials (RCTs) are considered as the
‘gold standard’ for evaluating health technologies, but
recruitment to trials remains problematic with the major-
ity failing to recruit to target and within time [1, 2]. This
results in either underpowered trials that cannot produce
robust results or, in some cases, extended recruitment,
which adds additional expense.
In spite of this there are very few trials evaluating differ-
ent strategies for recruiting clinicians and patients to clin-
ical trials. Recent systematic reviews of trials assessing
interventions for improving recruitment to trials found
only a limited numbers of relevant studies [3–5]. Further-
more, many of the included trials were small, likely to be
underpowered and unable to determine with any certainty
the magnitude of benefit. This is particularly true for
interventions that modified the method for approaching
potential participants. In addition, some of the included
studies were hypothetical trials where the host trial that
eligible patients were recruited to did not exist, and the
implications of their results for real trials are unclear [3].
Based on their findings, the review authors argued that
while the use of hypothetical trials to study recruitment in-
terventions has its place, trialists should include evaluations
of recruitment strategies within their trials, and research
funding bodies should support this as part of future trial
methodologies [3]. The lack of definitive results to make
strong recommendations was also highlighted in a Health
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Technology Assessment (HTA) into recruitment to clinical
trials [6]. The report recommended that future research
should focus on formally evaluating strategies aimed at in-
creasing recruitment and making trials more successful for
their effectiveness in a range of trials.
One way of doing this is to conduct trials of recruitment
strategies within host trials; that is to conduct embedded
recruitment trials. In order to maximise the impact of em-
bedded recruitment trials to the research community, they
need to be well reported. Critical appraisal of the quality
of clinical trials is possible only if the design, conduct, and
analysis of RCTs are thoroughly and accurately described
in published articles. Far from being transparent, the
reporting of RCTs is often incomplete [7]. Biased results
from poorly designed and reported trials can mislead
decision-making in health care at all levels, from treat-
ment decisions for the individual patient to formulation of
national public health policies [7].
A systematic review by Caldwell et al. [8] found
that, of the 37 embedded recruitment trials included,
only 12 trials (32 %) clearly reported allocation con-
cealment, two (4 %) specified blinding of outcome
assessors (no trial had blinding of participants to
intervention received as this would have been difficult
to achieve), 15 (40 %) recorded loss to follow-up
information, and 14 (38 %) used intention-to-treat
analysis. Similar findings were reported by Treweek et
al. [3], who found that although all trials in their re-
view were described by their authors as being either
randomised (n = 41) or quasi-randomised (n = 4), more
than a third failed to provide details of the method
used to achieve this. Similarly, while allocation con-
cealment was adequate in half of the trials, details
were poorly reported in many others. This was also
true in relation to the procedures used to blind par-
ticipants, which was often missing or not fully re-
ported. When considered across the domains, 12
trials had a low risk of bias, 13 had moderate risk
and 20 had a high risk.
In addition to being poorly reported, embedded trials
have some methodological characteristics that are atyp-
ical when compared with trials of effectiveness (such as
eligible population, sample size). These characteristics
affect their design, conduct, interpretation and reporting.
Currently there are no guidelines for reporting embed-
ded trials.
The Medical Research Council funded Systematic
Techniques for Assisting Recruitment to Trials (MRC
START) programme is designed to develop the concep-
tual and logistical framework for conducting embedded
recruitment trials and to assess their feasibility. It aims
to improve the evidence base concerning recruitment to
trials by developing a small number of recruitment inter-
ventions and testing these across multiple host RCTs,
enhance recruitment rates and make research more ac-
cessible to the public [9]. As part of the MRC START
programme we aim to develop guidelines for reporting
embedded recruitment trials. This manuscript describes
these guidelines and how they were developed.
We defined an embedded recruitment trial as a RCT
in which an intervention (or several interventions) to
enhance recruitment outcomes are tested in the context
of another RCT (or several RCTs) known as the host
RCT(s). Design and conduct of the embedded trial is
often constrained by its host RCT(s). It is important to
note that embedded recruitment trials may include
retention as an outcome; however, trials where embed-
ded intervention is aiming to improve retention exclu-
sively are excluded.
Methods
These guidelines were developed through an iterative
process following the general recommendations of the
EQUATOR (Enhancing the Quality and Transparency of
health Research) network on how to develop a reporting
guideline [10]. Systematic reviews by members of the
MRC START team [3] and others [8] had already
highlighted the need for these guidelines.
Generating items for inclusion in the checklist
Initial criteria were drawn up by SE, from reading nine
trial reports. The trials selected purposively were (a) one
very recent embedded recruitment trial with an MRC
START investigator as co-applicant [11] and thus likely
to provide a good indicator of the most up-to-date
reporting practice; (b) three recent trials of multi-media
interventions likely to be common in the future, and (c)
five recent embedded trials from a large systematic re-
view deemed to be at low risk of bias (and therefore we
assumed high quality). A second researcher (VM) com-
pared the initial criteria against the standard Consoli-
dated Standards for Reporting Trials (CONSORT)
statement 2010 [12] and identified items that could be
matched directly to the CONSORT checklist. Criteria
that could not be matched were identified as potential
new items. These items were then mapped to a CON-
SORT 2010 section heading.
These initial criteria were then presented to the MRC
START programme team at a face-to-face meeting for
discussion. The team suggested that these reporting
guidelines should extend to cover cluster randomised
embedded trials; nearly half of the embedded recruit-
ment trials in MRC START programme used cluster
randomised design (e.g. randomised to recruitment
intervention at practice or site level). We also agreed
that these guidelines should focus on prompting authors
to provide as much information as possible for readers,
to facilitate the adaption of successful recruitment
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strategies in future trials. Therefore, the MRC START
team agreed to add the proposed new items to the
provisional checklist. It was agreed that, although these
guidelines could apply to other embedded trials, the
primary focus of this work should be on embedded
recruitment trials.
Following these discussions, the initial checklist was
revised to incorporate cluster randomised embedded tri-
als, two new items were added ((1) a brief description of
host trial and (2) methods of collecting data) and, where
appropriate, item descriptors were amended so that they
were applicable to embedded trials. The revised checklist
contained 40 items. Where possible, good examples of
embedded trial reporting were added under each item.
Consensus meetings and pilot testing
We organised two face-to-face consensus meetings. The
first one was held in Manchester, UK in August 2014. This
meeting was open to the MRC START research team and
chief investigators of host trials involved in evaluating
MRC START recruitment interventions. Seven people
agreed to participate. Paper copies of the revised checklist
with examples were circulated to attendees.
SE and VM introduced each item to the group and
presented the rationale for inclusion, encouraging dis-
cussion. During the meeting, discussions of each poten-
tial item continued. As this work is partly designed to
support trial teams in writing up MRC START embed-
ded trials for publication, participants were encouraged
to share their views on how each item might apply to
their own trial and any reservations they had, usefulness
and any difficulties that they could foresee in applying
these guidelines to their own trials.
By the end of the discussions, we sought to come to
an agreement on each item in terms of whether it should
be included as a checklist item, how each item may
apply to embedded trials, justification for inclusion and
descriptor wording. At the end of the meeting, two trial
teams agreed to pilot-test the preliminary reporting
guidelines. Before the second consensus meeting, draft
reporting guidelines were updated incorporating the
feedback from the day and from the pilot trials.
The second consensus meeting was held in Manchester,
UK in October 2014. The purpose of this meeting was to fi-
nalise the provisional reporting checklist. External experts
as well as members of the MRC START Group were in-
vited to this meeting. Attendees included review authors,
methodologists, statisticians, medical journal editors and
chief investigators or managers from MRC START host tri-
als. The revised draft reporting guidelines document was
circulated to all who agreed to attend before the meeting.
Thirteen people attended. Following preliminary introduc-
tions to the MRC START programme and its objectives, SE
introduced each checklist item, presented the rationale for
inclusion and opened the floor for discussion. During the
meeting, arguments for and against the inclusion of each
potential item continued. At the meeting, we sought to
reach consensus on the final checklist, descriptor wording
and explanations. It was agreed that this guideline should
be used in conjunction with other relevant reporting guide-
lines, in line with CONSORT recommendations [7]. Thus,
specific additions relating to cluster randomised trials were
removed.
Post-meeting activities
After the meeting, SE and VM met on three occasions to fi-
nalise the descriptor wording, explanations and examples.
Revised reporting guidelines were circulated via e-mail to
all attendees (consensus meeting 1 and 2 attendees) for
comments. All suggestions for revision were addressed.
Further, we reviewed the CONSORT guidelines for ab-
stracts against the finalised checklist items for reporting
embedded recruitment trials to identify any additional
items that need to be reported within an abstract of an
embedded trial as essential.
Recommendations for reporting embedded recruitment
trials
The revised checklist for reporting embedded recruitment
trials was developed in line with the CONSORT statement
2010 [12]. The CONSORT statement provides a list of es-
sential items to include when reporting randomised trials.
Our revised checklist does not include additional items to
be reported as essential for embedded recruitment trials.
However, we have extended some items to cover specific
reporting requirements of these trials (Table 1). Further,
we have provided extensive explanations for such recom-
mendations made. We have used a number of examples
to illustrate how embedded trials may adhere to those
CONSORT items particularly relevant to them and spe-
cific requirements that we have highlighted. These include
how best to deal with the description of the host trial, the
importance of describing items that may differ in the host
and embedded trials such as the setting and the eligible
population, and the importance of identifying clearly the
point at which the recruitment intervention embedded in
the host trial. Further examples of good reporting are pro-
vided in Additional file 1.
Table 1 presents the checklist of items to include when
reporting embedded recruitment trials. This article also
provides the rationale and meaning of each criterion in the
context of embedded recruitment trials and for most items,
at least one published example of good reporting is pro-
vided. Several examples of CONSORT flow diagrams are
also included. In these examples, authors’ references to
other publications were removed to avoid confusion. The
recommendations in this paper should be seen as additional
to the general guidance in the main CONSORT
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Table 1 Checklist of items for reporting embedded recruitment trials
Section/topic and item no. CONSORT 2010 (standard) checklist item Extension for embedded recruitment trials
Title and abstract
1a Identification as a randomised trial in the title Identification as an embedded randomised recruitment trial in
the title
1b Structured summary of trial design, methods,
results, and conclusions (for specific guidance
see CONSORT for abstracts)
Structured summary of embedded recruitment trial design,
methods, results, and conclusions (for specific guidance see
CONSORT for abstracts)
Introduction
Background and objectives
2a Scientific background and explanation of
rationale
Scientific background and explanation of rationale for the
embedded recruitment trial including a brief description of the
host trial(s) as appropriate
2b Specific objectives or hypotheses Specific objectives or hypotheses for the embedded
recruitment trial
Methods
Trial design
3a Description of trial design (such as parallel,
factorial) including allocation ratio
Description of embedded recruitment trial design
(such as parallel, factorial, cluster) including allocation ratio
3b Important changes to methods after trial
commencement (such as eligibility criteria),
with reasons
Important changes to methods of the embedded recruitment
trial after commencement (such as eligibility criteria), with
reasons
Participants
4a Eligibility criteria for participants Eligibility criteria for participants for the embedded recruitment
trial, including any differences from those for the host trial(s)
4b Settings and locations where the data were
collected
Settings and locations where the embedded recruitment trial
was carried out, including a brief description of the host trial(s)
as appropriate
Interventions
5 The interventions for each group with
sufficient details to allow replication, including
how and when they were actually
administered
The interventions for each group (including control group)
within the embedded recruitment trial with sufficient details to
allow replication, including how, where and when they were
actually administered
Outcomes
6a Completely defined pre-specified primary and
secondary outcome measures, including how
and when they were assessed
Completely defined pre-specified primary and secondary
outcome measures for the embedded recruitment trial,
including how and when they were assessed
6b Any changes to trial outcomes after the trial
commenced, with reasons
Any changes to embedded recruitment trial outcomes after
the embedded recruitment trial commenced, with reasons
Sample size
7a How sample size was determined How sample size for the embedded recruitment trial was
determined
7b When applicable, explanation of any interim
analyses and stopping guidelines
When applicable, explanation of any interim analyses and
stopping guidelines for the embedded recruitment trial
Randomisation
Sequence generation
8a Method used to generate the random
allocation sequence
Method used to generate the random allocation sequence
for the embedded recruitment trial
8b Type of randomisation; details of any
restriction (such as blocking and block size)
Type of randomisation; details of any restriction (such as
blocking and block size) in the embedded recruitment trial
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Table 1 Checklist of items for reporting embedded recruitment trials (Continued)
Allocation concealment mechanism
9 Mechanism used to implement the random
allocation sequence (such as sequentially
numbered containers), describing any steps
taken to conceal the sequence until
interventions were assigned
Mechanism used in the embedded recruitment trial to
implement the random allocation sequence (such as
sequentially numbered containers), describing any steps taken
to conceal the sequence until interventions were assigned
Implementation
10 Who generated the random allocation
sequence, who enrolled participants, and who
assigned participants to interventions?
Who generated the random allocation sequence(s), who
enrolled participants, and who assigned participants to
embedded recruitment interventions?
Blinding
11a If done, who was blinded after assignment to
interventions (for example, participants, care
providers, those assessing outcomes) and
how?
If done, who was blinded after assignment to embedded
recruitment interventions (for example, participants, care
providers, those assessing outcomes) and how?
11b If relevant, description of the similarity of
interventions
If relevant, description of the similarity of interventions in the
embedded recruitment trial
Statistical methods
12a Statistical methods used to compare groups
for primary and secondary outcomes
Statistical methods used to compare groups for primary and
secondary outcomes of the embedded recruitment trial
12b Methods for additional analyses, such as
subgroup analyses and adjusted analyses
Methods for additional analyses, such as subgroup analyses
and adjusted analyses for the embedded recruitment trial
Results
Participant flow (a diagram is strongly recommended)
13a For each group, the numbers of participants
who were randomly assigned, received
intended treatment, and were analysed for
the primary outcome
For each group in the embedded recruitment trial, the
numbers of participants who were randomly assigned,
received intended treatment, and were analysed for the
primary outcome
13b For each group, losses and exclusions after
randomisation, together with reasons
For each group, losses and exclusions after randomisation to
the embedded recruitment trial, together with reasons
Recruitment
14a Dates defining the periods of recruitment and
follow-up
Dates defining the periods of recruitment and follow-up for
both embedded recruitment trial and host trial(s)
14b Why the trial ended or was stopped Why the embedded recruitment trial ended or was stopped
Baseline data
15 A table showing baseline demographic and
clinical characteristics for each group
If possible a table showing baseline characteristics of each arm
of the embedded recruitment trial
Numbers analysed
16 For each group, number of participants
(denominator) included in each analysis and
whether the analysis was by original assigned
groups
For each group in the embedded recruitment trial, number of
participants (denominator) included in each analysis and
whether the analysis was by original assigned groups
Outcomes and estimation
17a For each primary and secondary outcome,
results for each group, and the estimated
effect size and its precision (such as 95 %
confidence interval)
For each primary and secondary outcome, results for each
group in the embedded recruitment trial, and the estimated
effect size and its precision (such as 95 % confidence interval)
17b For binary outcomes, presentation of both
absolute and relative effect sizes is
recommended
For binary outcomes in the embedded recruitment trial,
presentation of both absolute and relative effect sizes is
recommended
Ancillary analyses
18 Results of any other analyses performed,
including subgroup analyses and adjusted
analyses, distinguishing pre-specified from
exploratory
Results of any other analyses performed for the embedded
recruitment trial, including subgroup analyses and adjusted
analyses, distinguishing pre-specified from exploratory
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explanatory paper [7] and, where relevant, other CON-
SORT guidance such as CONSORT extension to cluster
randomised trials.
Title and abstract
Item 1a
Standard CONSORT 2010 item: identification as a ran-
domised trial in the title.
Extension for embedded recruitment trial: identification
as an embedded randomised recruitment trial in the title.
Example:
Improving recruitment to a study of telehealth man-
agement for long-term conditions in primary care: two
embedded RCTs of optimised patient information
material [13].
Explanation:
The importance of RCTs that test the effectiveness of dif-
ferent approaches to recruitment has been highlighted:
‘The most robust test of the effectiveness of a recruitment
method is an RCT comparing one method with an alterna-
tive, “nested” in a real “host” trial [9]’. Embedding RCTs
within host RCTs not only provides a platform for conduct-
ing recruitment research but also could be used in other
methodological research into design and conduct of RCTs
[14], for example, research on retention in RCTs. Though
embedded trials are less common than RCTs of treatment
effectiveness, they provide much needed research evidence
for trialists. We recognise that at present there are no
widely used terms to distinguish these trials. Several reviews
on trial methods have highlighted the challenges in identify-
ing relevant research studies through electronic database
searches [14, 15]. Consistent use of the term ‘embedded’ in
trial titles would ensure that such methodological studies
are more easily identifiable and distinguished from other
RCTs.
We therefore strongly encourage adding the term ‘em-
bedded randomised trial’ in the title to ensure that these
trials are identifiable in electronic database searches. We
prefer to use the term ‘embedded’ instead of ‘nested’, to
ensure that these trials are not confused with other
study designs such as nested case-control studies, where
only a subgroup of the original study population is in-
cluded in the nested study.
Further, we suggest that the term ‘recruitment’ is
added to describe the focus of embedded interventions.
Item 1b
Standard CONSORT 2010 item: structured summary of
trial design, methods, results, and conclusions (for spe-
cific guidance see CONSORT for abstracts [16]).
Table 1 Checklist of items for reporting embedded recruitment trials (Continued)
Harms
19 All important harms or unintended effects in
each group (for specific guidance see
CONSORT for harms)
All important harms or unintended effects in each group
for both the embedded recruitment trial and host trial(s)
(for specific guidance see CONSORT for harms)
Discussion
Limitations
20 Trial limitations, addressing sources of
potential bias, imprecision, and, if relevant,
multiplicity of analyses
Embedded recruitment trial limitations, addressing sources of
potential bias, imprecision, and, if relevant, multiplicity of
analyses
Generalisability
21 Generalisability (external validity, applicability)
of the trial findings
Generalisability (external validity, applicability) of the
embedded recruitment trial findings
Interpretation
22 Interpretation consistent with results,
balancing benefits and harms, and
considering other relevant evidence
Interpretation consistent with results of the embedded
recruitment trial, balancing benefits and harms, and
considering other relevant evidence
Other information
Registration
23 Registration number and name of trial registry Registration number and name of trial registry
(for all host trials and embedded recruitment trial if available)
Protocol
24 Where the full trial protocol can be accessed,
if available
Where the embedded recruitment trial protocol can be
accessed, if available
Funding
25 Sources of funding and other support
(such as supply of drugs), role of funders
For the embedded recruitment trial, sources of funding and
other support, role of funders and collaborators
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Extension for embedded recruitment trial: structured
summary of embedded recruitment trial design, methods,
results, and conclusions (for specific guidance see CON-
SORT for abstracts [16]).
Example:
We recommend that embedded recruitment trials
should follow the CONSORT abstract guidelines for
reporting abstracts. We have used an abstract from a
published journal article [17] to illustrate how embedded
recruitment trials may strive to adhere to CONSORT
abstract guidelines [16]. Here we have enhanced the ori-
ginal abstract to incorporate specific reporting require-
ments that we have recommended for embedded
recruitment trials (see Fig. 1).
Explanation:
No additional items were identified for reporting
within the abstracts of embedded recruitment trials.
However, authors must pay special attention to specific
requirements that we have highlighted for some of the
essential items in the checklist. Additional information
that we have recommended on those items should be re-
ported in abstracts.
Introduction: background and objectives
Item 2a
Standard CONSORT 2010 item: scientific background
and explanation of rationale.
Extension for embedded recruitment trial: scientific
background and explanation of rationale for the embed-
ded recruitment trial including a brief description of the
host trial(s) as appropriate.
Example:
Randomised controlled trials are the ‘gold standard’ for
the evaluation of the effectiveness and safety of health
care interventions, particularly because they protect
against selection bias. However, recruiting clinicians and
patients to randomised trials can be extremely difficult.
Trialists use many interventions to improve recruitment,
but evidence regarding the likely effect of these interven-
tions is often unclear.
The web-based intervention modelling experiment
(WIME) study (ClinicalTrials.gov number NCT01206738)
has the primary aim of running a WIME to develop and
evaluate theory-based interventions to improve antibiotic
prescribing for upper respiratory tract infections in pri-
mary care. It also has an embedded trial evaluating which
of two invitation methods, e-mail or post, is most effective
at recruiting general practitioners (GPs) to the study,
which is the subject of this article [11].
Explanation:
The CONSORT statement encourages authors to de-
scribe the problem that necessitated the work [18]. The
need for an embedded trial of alternative recruitment
approaches may have been identified prior to the host
trial commencing and planned alongside the host trial
(e.g. Treweek et al. [11]). Alternatively, trial methodolo-
gists interested in evaluating new recruitment approaches
may collaborate with suitable host trials for embedding re-
cruitment trials (e.g. Man et al. [13], see Additional file 1,
Item 2a, example 1).
Lastly, recognition of the need for an embedded trial of
different recruitment strategies may have arisen from on-
going recruitment difficulties in the host trial(s) (e.g. Ford
et al. [19], see Additional file 1, Item 2a, example 2). In
such cases the nature, scope, and severity of the problem
is an intrinsic part of the background and provides a com-
pelling rationale for the embedded trial. Furthermore, an
embedded trial is always conducted in the context of its
host RCT(s). Therefore, embedded recruitment trial re-
ports should provide sufficient information (such as
population, intervention, settings and reference(s) to
descriptions of host trial(s), e.g. protocol or findings)
about the host trial(s) and their recruitment processes
or issues to understand the context of the embedded
recruitment trial.
In most recruitment trials we have used as examples
for this guideline, the brief description of the host trial
was given in the background. We therefore suggest that
this may be the most appropriate place to locate such a
description, but we acknowledge that sometimes the
brief description of the host trial will sit better at a later
point in the manuscript, in relation to the embedded
trial setting (see item 4b).
If the embedded recruitment trial was not planned in
response to specific recruitment difficulties in the host
trial, authors’ rationale for the embedded trial must,
nevertheless, be clearly explained (e.g. Treweek et al.
[11], Man et al. [13]).
Item 2b
Standard CONSORT 2010 item: specific objectives or
hypotheses.
Extension for embedded recruitment trial: specific ob-
jectives or hypotheses for the embedded recruitment trial.
Example:
To assess whether optimised patient information ma-
terials improved the proportion of patients responding
positively to an invitation to take part in each trial and
the proportion actually randomised [13].
Explanation:
Explanations for reporting specific objectives and hypoth-
esis of the study clearly are discussed by Moher et al. [7].
Methods: trial design
Item 3a
Standard CONSORT 2010 item: description of trial de-
sign (such as parallel, factorial) including allocation ratio
Madurasinghe Trials  (2016) 17:27 Page 7 of 25
Fig. 1 Example abstract for an embedded recruitment trial [17]
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Extension for embedded recruitment trial: description
of embedded recruitment trial design (such as parallel,
factorial, cluster) including allocation ratio.
Example:
We used a 2 × 2 factorial design to distribute practices
and participants across two trial design factors: cluster
versus individual allocation and systematic versus oppor-
tunistic recruitment.
We randomly assigned 24 practices (8 practices in each
of 3 geographical regions (Bristol, Devon and Coventry))
in a 3:1 ratio to cluster (practice) allocation or individual
allocation, and in a 1:1 ratio to opportunistic or systematic
recruitment [20].
Explanation:
These guidelines apply to all embedded recruitment
trials. As many embedded trials are cluster randomised
(for example, in the MRC START programme 7 out of
11 embedded recruitment trials were cluster rando-
mised), we have added this to the list of designs given as
examples in the item descriptor. For additional informa-
tion required in reporting other trial designs such as
cluster randomised trials, refer to appropriate CON-
SORT extensions.
Item 3b
Standard CONSORT 2010 item: important changes to
methods after trial commencement (such as eligibility
criteria), with reasons.
Extension for embedded recruitment trial: important
changes to methods of the embedded recruitment trial after
commencement (such as eligibility criteria), with reasons.
Example:
In a primary prevention trial with postmenopausal hor-
mone therapy (PHT; also known as hormone replacement
therapy, HRT), we wanted to study the effect on numbers
recruited and the process of recruitment when using
blinding (the blind group) as compared to the situation
when both the caregiver and the woman will know which
arm the woman is in (the non-blind group).
In the original study protocol, ultrasound examination
of the uterus in the non-blind group was to be made
only in the PHT arm and only after the envelope had
been opened; however, physicians wanted to provide a
clinical service for the women, and most women in the
non-blind group were examined before the opening of
the envelope [21].
Explanation:
Moher et al. [7] provides detailed explanations for
reporting important changes to methods after trial
commencement.
Participants
Item 4a
Standard CONSORT 2010 item: eligibility criteria for
participants.
Extension for embedded recruitment trial: eligibility
criteria for participants for the embedded recruitment
trial, including any differences from those for the host
trial(s).
Example:
Patients were eligible for the study if they (1) had a
diagnosis of colorectal, breast or lung cancer; (2) were
clinically eligible for entry into a cancer treatment trial
randomised against control/standard treatment, or best
supportive care; (3) had access to a video recorder, CD-
ROM or DVD playing facilities; and (4) could under-
stand English [22].
Explanation:
The embedded trial eligibility criteria may or may not
be identical to that for the host trial(s) (e.g. Man et al.
[13], see Additional file 1, Item 4a, example 1). For ex-
ample, the embedded trial may focus on a subgroup of
participants for practical or other reasons (e.g. Hutchinson
et al. [22]) or where recruitment to host trial(s) was a par-
ticular issue or it may include a wider group, with the view
of identifying potential participants eligible for host tri-
al(s), who will then be included in the host trial based on
more restrictive inclusion criteria (e.g. Tworoger et al.
[23], see Additional file 1, Item 4a, example 2). Eligibility
criteria for the embedded trial therefore should be clearly
defined and should explicitly state whether this did or did
not differ from the host trial(s).
Item 4b
Standard CONSORT 2010 item: settings and locations
where the data were collected.
Extension for embedded recruitment trial: settings and
locations where the embedded recruitment trial was
carried out, including a brief description of the host
trial(s) as appropriate.
Example:
Those eligible for enrolment in the study were HIV-1
positive men and women attending the HIV clinic at the
Chelsea and Westminster Hospital in west London be-
tween January 1997 and June 1998. Specific clinics
where the physicians were involved in clinical trials and
known to refer patients to trials were targeted, and all
patients attending that clinic were asked if they would
like to join this study [24].
Explanation:
Careful descriptions of the trial participants and the
setting in which they were studied are needed so that
readers may assess the external validity (generalisability)
of the trial results [18]. Often settings and locations for
the embedded trial are constrained by its host trial.
Therefore, if a brief description of the host trial(s)
setting is not provided in the introduction, this could
be an appropriate place to add it (e.g. Kiernan et al.
[25], Coyne et al. [26], see Additional file 1, Item 4b,
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examples 1–2). Such descriptions, whether here or in the
introduction would normally include simple statements
about the population, aim (or equivalently intervention
and outcome) and reference(s) to descriptions of host
trial(s).
It is important to note, however, the recruitment inter-
vention in the embedded trial may not necessarily be
conducted in the same setting as the intervention in the
host trial (e.g. Ives et al. [24]). Further examples of clin-
ical trials recruiting participants in different locations/
settings to where the interventions were carried out are
found in trials using media campaigns for recruitment
[27, 28]. Settings and locations for the embedded trial
must therefore be clearly reported.
Interventions
Item 5
Standard CONSORT 2010 item: the interventions for
each group with sufficient details to allow replication, in-
cluding how and when they were actually administered.
Extension for embedded recruitment trial: the inter-
ventions for each group (including control group) within
the embedded recruitment trial with sufficient details to
allow replication, including how, where and when they
were actually administered.
Example:
Our investigation was a single-blind RCT conducted
within the organisational structure established for the
management of clinical sites in ADVANCE. Within this
structure the usual route for communication of informa-
tion was from the central trial coordinators based at the
International Coordinating Centre in Sydney, Australia,
to one of five Regional Coordinating Centres (Beijing,
London, Melbourne, Montreal, Utrecht) who then
passed on information to the clinical sites (Fig. 2). This
structure included little direct communication between
the central trial coordinators in Sydney and the clinical
sites, and it was the effect of instituting additional com-
munication between central coordinators and the clinical
centres that was evaluated in the trial reported here.
Control—usual communications
Usual communications to the clinical sites were provided
via the Regional Coordinating Centres with the Inter-
national Coordinating Centre providing only occasional
direct communications in the form of generic newsletters,
e-mails and faxes. The Regional Coordinating Centres pro-
vided routine monitoring activities, which included fre-
quent telephone, e-mail and personal contacts to support
recruitment activities.
Intervention—additional communications.
The additional communication strategy was applied on
top of the usual communication strategy. The additional
communication strategy from the central trial coordina-
tors to the clinical sites involved frequent e-mail contact,
regular personalised mail-outs of league tables and graphs
describing recruitment performance relative to other
centres, individualised certificates acknowledging achieve-
ment of recruitment milestones, and items related to the
study (e.g. an ‘ADVANCE computer mouse-mat’). E-mails
to the clinical sites from the central trial coordinators gen-
erally contained highly-tailored site-specific information
about recruitment performance relative to goals, along
with messages of support and encouragement. On aver-
age, sites assigned to the intervention received about one
of these additional pieces of communication intended to
enhance recruitment from the International Coordinating
Centre each month [29].
Explanation:
It is important to note that interventions in the em-
bedded trial are always directed towards a host trial(s).
Some embedded trial interventions may test different
trial designs (illustrated in Avenell et al. [30], see
Additional file 1, Item 5, example 1). Others may focus
on trial procedures, for example, Monaghan et al. [29]
evaluated the effects of different communication proce-
dures between central coordinators and the clinical sites
on participant accrual. Therefore, authors should
clearly report the aspect of the host trial(s) (i.e. pro-
cedures or design itself ) targeted by the recruitment
intervention in the embedded trial. It is strongly rec-
ommended that the focal point in the host trial tar-
geted by recruitment intervention is illustrated in a
flow chart. This could be part of the CONSORT flow
chart for the host trial, but often it will be easier to
illustrate in a separate flow chart (Monaghan et al.
[29], Fig. 2 and Free et al. [31], see Additional file 1,
Item 5, example 2; Fig. 3).
The description of the recruitment intervention may
include details such as form and content, format and,
if applicable, any extra features such as incentives, timing
Fig. 2 Flow chart illustrating intervention and control sites and route
of additional communication strategy
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of delivery, methods of reminders/follow-up and how un-
delivered invitations were treated. A template for
reporting intervention descriptions is provided in
Hoffmann et al. [32].
Outcomes
Item 6a
Standard CONSORT 2010 item: completely defined pre-
specified primary and secondary outcome measures, in-
cluding how and when they were assessed.
Extension for embedded recruitment trial: completely
defined pre-specified primary and secondary outcome
measures for the embedded recruitment trial, including
how and when they were assessed.
Example:
The primary study end point was the percentage of
patients in the study who declined participation in the
clinical trial that was presented to them.
Data were collected from patient case notes and dir-
ectly from questionnaires. Patients were seen on two oc-
casions for the purposes of this trial. These visits were
part of patients’ general medical care, as they were at-
tending the hospital anyway on these days. These were
known as ‘visit 1’ (explanation of treatment trial) and
‘visit 2’ (return visit, usually 1 week later, to discuss their
decision). Demographic data on all patients who were
approached for the AVPI study were collected and en-
tered into a log sheet [22].
Explanation:
Primary and secondary outcome measures for embed-
ded recruitment trials must be considered separately
from the host trial(s). Types of outcome may include
acceptance and decline rates (e.g. Hutchinson et al.
[22]), recruitment rates, retention rates, time to
complete recruitment, consenting rates, quality of in-
formed consent and time and cost incurred. It is import-
ant to note that acceptance and decline rates are not
necessarily the same outcome with direction reversed.
For example, to be considered as a valid acceptance or de-
cline of the invitation (i.e. recruitment intervention), pa-
tients may be required to return an acceptance or decline
form actively. In this case, non-responders do not fulfil
the pre-defined criteria for a valid acceptance nor a de-
cline of the invitation (e.g. Man et al. [13], see Additional
file 1, Item 6a). For each outcome, the definitions for de-
nominators must be clearly reported and for rates, numer-
ators must also be clearly reported.
It is important to consider that the primary and
secondary end points of an embedded recruitment
trial do not generally coincide with those of the host
trial (e.g. Hutchinson et al. [22]). For readers to be able
to assess outcomes reliably, information on the data col-
lection process (what was collected, when and how) for
the embedded recruitment trial must be clearly reported.
Item 6b
Standard CONSORT 2010 item: any changes to trial
outcomes after the trial commenced, with reasons.
Extension for embedded recruitment trial: any changes
to the embedded recruitment trial outcomes after the
embedded recruitment trial commenced, with reasons.
Example:
In the Healthlines Depression recruitment trial, the pri-
mary outcome was the proportion of patients randomised.
Fig. 3 A flow chart illustrating the focal point(s) of the host trial recruitment pathway targeted by embedded recruitment trial interventions
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Secondary outcomes were the proportion of patients who
accepted the offer of invitation to participate, and the pro-
portion of eligible patients who actively opted out of the
trial (i.e. returned a ‘decline’ form).
In the Healthlines CVD recruitment trial, the primary
outcome was the proportion of patients who responded
positively to the invitation to participate. This, rather than
actual randomisation, was selected as the primary out-
come because of a cap on recruitment numbers, whereby
only the first 25 eligible participants were randomised in
each practice. This upper limit was implemented because
of practice staff availability to carry out these assessments,
and an initial agreement with researchers that 25 patients
would be sufficient to reach target recruitment across par-
ticipating GP practices. The secondary outcome was the
proportion of eligible patients who actively opted out [13].
Explanation:
A detailed explanation for reporting important changes
to methods after trial commencement was provided by
Moher et al. [7].
Item 7a
Standard CONSORT 2010 item: how sample size was
determined.
Extension for embedded recruitment trial: how sample
size for the embedded recruitment trial was determined.
Example:
This was a pragmatic trial, so we included all partici-
pants on the ‘outstanding public interest list’ for the
Txt2stop trial. In June 2008 there were 937 potential
participants on the ‘outstanding public interest’ list. A
sample size of 937 gives a 90 % chance of detecting an
absolute difference of 4.5 % in registrations (6.5 % in the
intervention group compared to 2 % in the control
group) at a two-sided alpha = 0.05 [31].
Explanation:
It should be noted that in many embedded trials of re-
cruitment interventions, the numbers of eligible patients
potentially available for the embedded trial may be far
larger than the sample size calculated for the host trial.
For example, if a trial recruiting 500 patients estimates a
10 % participation rate, there may be 5000 eligible pa-
tients for the embedded trial.
However, because of the restrictions posed by their
host trial(s), it is not necessarily appropriate for embed-
ded trials to estimate and set a target sample size cap-
able of detecting the minimally important difference in
its primary outcome. For example, if the number of par-
ticipants required for the host trial is known, then the
maximum number of patients that the embedded trial
can approach is as many eligible participants as it takes to
recruit that number (although the number approached
may be smaller). Here, performing a sample size calcula-
tion for number of participants to be approached in the
embedded trial is not meaningful. In such cases, authors
should clearly report how the sample size has been deter-
mined (e.g. Treweek et al. [11], see Additional file 1, Item
7a, example 1). However, it is usually possible to report
the expected sample size and effect sizes that are detect-
able at 80 % or 90 % power for the embedded trial, based
on host trial(s) requirements, if certain assumptions are
made (e.g. Free et al. [31]). Where formal sample size cal-
culations have been performed, these should be reported
(e.g. Hutchinson et al. [22], see Additional file 1, Item 7a,
example 2).
Item 7b
Standard CONSORT 2010 item: when applicable, explan-
ation of any interim analyses and stopping guidelines
Extension for embedded recruitment trial: when ap-
plicable, explanation of any interim analyses and stop-
ping guidelines for the embedded recruitment trial
We have not included examples or explanations for
this item as there are no additional recommendations
made specifically relevant for embedded recruitment tri-
als. Rationale for reporting this item is provided by
Moher et al. [7].
Randomisation: sequence generation
Item 8a
Standard CONSORT 2010 item: method used to gener-
ate the random allocation sequence.
Extension for embedded recruitment trial: method
used to generate the random allocation sequence for the
embedded recruitment trial.
Example:
A de-identified list of eligible participants (that is a list
of unique study numbers corresponding to the eligible
participants but containing no personal identifiers) was
prepared by the research nurse. To ensure concealment
of allocation, one of the investigators (JJY), who was not
directly involved in the recruitment of the patients from
family physicians’ offices and who was unaware of the
patients’ identities, produced a computer-generated ran-
domisation sequence (block size 4) stratified by family
practice. This investigator (JJY) then allocated each
unique study number to either telephone or mail follow-
up (in a 1:1 ratio) according to the randomisation se-
quence and returned the participant allocation list to the
research nurse [17].
Explanation:
Detailed explanations on why this item should be re-
ported clearly were given in Altman et al. [18] and
Moher et al. [7].
Item 8b
Standard CONSORT 2010 item: type of randomisation;
details of any restriction (such as blocking and block size)
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Extension for embedded recruitment trial: type of ran-
domisation; details of any restriction (such as blocking
and block size) in the embedded recruitment trial.
Example:
Patients were first stratified on the basis of age and
type of randomised clinical trial for which consent was
sought: trials comparing treatment with no treatment;
trials comparing dissimilar treatments; and trials com-
paring similar treatments [33].
Explanation:
As for any RCT, in embedded trials a sensible evalu-
ation and choice of stratification/minimisation factors is
called for (e.g. Avenell et al. [30], see Additional file 1,
Item 8b). Where the host trial is using cluster random-
isation, and the embedded trials also use cluster ran-
domisation, it is important that the allocation of the
recruitment intervention is balanced over the host clus-
ters. There may be a risk of unbalanced allocation where
the number of clusters is small, and any mechanisms
used to ensure balance should be described. If the re-
cruitment trial is embedded in more than one host trial,
the host trial itself could be an important factor influen-
cing recruitment outcomes. For an example, the baseline
recruitment rates across different patient populations in-
cluded in host trials may differ. Similarly, the responses
for embedded recruitment intervention may differ be-
cause of the differential acceptability of the recruitment
interventions and other trial-specific aspects of the de-
sign in different host trials. Where there are multiple
host trials, therefore, the host trial should be considered
as a possible stratification or minimisation factor for em-
bedded trials, e.g. Simes et al. [33].
Allocation concealment mechanism
Item 9
Standard CONSORT 2010 item: mechanism used to im-
plement the random allocation sequence (such as sequen-
tially numbered containers), describing any steps taken to
conceal the sequence until interventions were assigned)
[49].
Extension for embedded recruitment trial: mechan-
ism used in the embedded recruitment trial to imple-
ment the random allocation sequence (such as
sequentially numbered containers), describing any steps
taken to conceal the sequence until interventions were
assigned.
Example:
A randomisation list was generated using a random
numbers table and held centrally at the Data Coordinat-
ing Centre. The research nurse obtained each partici-
pant’s allocation assignment by phone from a member of
the study staff [34].
Explanation:
Altman et al. [18] and Moher et al. [7] provide detailed
explanations for including this item.
Implementation
Item 10
Standard CONSORT 2010 item: who generated the ran-
dom allocation sequence, who enrolled participants, and
who assigned participants to interventions?
Extension for embedded recruitment trial: who gener-
ated the random allocation sequence(s), who enrolled
participants, and who assigned participants to embedded
recruitment interventions?
Example:
The study statistician (GM) generated a list of random
numbers and participant IDs broken down into mailing
blocks, which SPCRN used to randomly allocate GPs to
receive either an e-mail or a postal invitation on a 1:1
basis without stratification [11].
Explanation:
Altman et al. [18] and Moher et al. [7] provide detailed
explanations for reporting this item.
Blinding
Item 11a
Standard CONSORT 2010 item: if done, who was
blinded after assignment to interventions (for example,
participants, care providers, those assessing outcomes)
and how?
Extension for embedded recruitment trial: if done,
who was blinded after assignment to embedded recruit-
ment interventions (for example, participants, care pro-
viders, those assessing outcomes) and how?
Example:
Although participants were aware of their group status
(i.e. whether or not they received a telephone call or a
questionnaire), they were unaware of the other groups’
status and that recruitment into the study was being
monitored on the basis of this, as part of a RCT. It was
impractical for the research nurse administering the in-
terventions (posting out questionnaires and contacting
people by telephone) and assessing the outcome (recruit-
ment into physical activity study) to be blinded to their
group status [35].
Explanation:
In controlled trials, the term blinding usually refers to
keeping study participants, health care providers, and
sometimes those collecting and analysing clinical data un-
aware of the assigned intervention, so that they will not be
influenced by that knowledge [18]. Blinding means more
than just keeping the name of the treatment hidden. In
drug trials, ‘patients may well see the treatment being
given to patients in the other treatment group(s), and the
appearance of the drug used in the study could give a clue
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to its identity. Differences in taste, smell, or mode of deliv-
ery may also influence efficacy, so these aspects should be
identical for each treatment group. Even colour of medica-
tion has been shown to influence efficacy. In studies com-
paring two active compounds, blinding is possible using
the “double dummy” method. For example, if we want to
compare two medicines, one presented as green tablets
and one as pink capsules, we could also supply green pla-
cebo tablets and pink placebo capsules so that both groups
of patients would take one green tablet and one pink cap-
sule’ [36]. In recruitment trials, however, both participants
and providers are aware of the intervention they receive/
deliver.
For example, in an embedded recruitment trial testing
two types of invitation letters, both participants and inter-
vention providers have the full knowledge of what they had
(i.e. wording, format, lettering, and colour of the invitation
letter). Therefore, it is not possible to keep them blind to
the intervention (i.e. to keep what treatment group they
are being assigned to hidden from them). In these situa-
tions, researchers may consider blinding the participants/
providers to the existence of other treatment arms or to
the embedded trial altogether. This was the case in the
Harris et al. [35], for example.
Thus, while information that is often withheld in
placebo-controlled trials, about which treatment the par-
ticipants are getting cannot be withheld, information
that is often given to participants about the trial and
arms other than those they are allocated to is withheld.
Furthermore, consent to participate is extremely un-
likely in these trials since it does not usually make any
sense to ask individuals if they would like to take part in
a trial of recruitment strategies—this would not make
the results of the trial relevant to real practice and would
probably result in reduced recruitment rates, the very
opposite of the recruitment RCT aim.
This withholding of information is, in some sense, an
alternative form of blinding and in embedded recruit-
ment trials: therefore, to assess whether participant/pro-
vider blinding was achieved in any meaningful way, the
information given to participants/providers about the
embedded trial must be clearly reported. For example,
Harris et al. [35], Lienard et al. [37] and Monaghan et al.
[29] (see Additional file 1, Item 11a, examples 1–2) re-
ported clear details about the information that was given
to or withheld from those approached.
Item 11b
Standard CONSORT 2010 item: if relevant, description
of the similarity of interventions.
Extension for embedded recruitment trial: if relevant,
description of the similarity of interventions in the
embedded recruitment trial.
Example:
Both units received identical literature about the study,
received the same slide presentation on the study proto-
col, and had the same opportunity to ask questions. This
scripting was designed to ensure consistency between
units and minimise potential sources of bias [38].
Explanation:
In any RCT, for successful blinding and therefore elim-
ination of bias, it is important that all elements of the
trial except the intervention that is being evaluated are
kept the same across all arms. Further, this will ensure
that the outcome(s) of interest are not unduly influenced
by other trial aspects (for example environment of the
room where interventions administered). While blinding
in the usual sense may not be possible in embedded re-
cruitment trials (see item 11a) it is still important that
apart from the active interventions, all other aspects of
the intervention are similar in order to avoid bias. For
example, in Fowell et al. [38] the active interventions
were cluster randomisation versus randomised consent
but other aspects were identical in both arms.
Statistical methods
Item 12a
Standard CONSORT 2010 item: statistical methods used
to compare groups for primary and secondary outcomes.
Extension for embedded recruitment trial: statistical
methods used to compare groups for primary and sec-
ondary outcomes of the embedded recruitment trial.
Example:
Outcomes were first described separately by arm, and
then compared using logistic regression to estimate the
between-group odds ratio (OR) and corresponding 95 %
confidence interval (CI) on the basis of the intention-to-
treat principle [13].
Explanation:
Rationale for reporting statistical methods used to
compare groups is given by Altman et al. [18] and
Moher et al. [7].
Item 12b
Standard CONSORT 2010 item: methods for additional
analyses, such as subgroup analyses and adjusted analyses.
Extension for embedded recruitment trial: methods for
additional analyses, such as subgroup analyses and ad-
justed analyses for the embedded recruitment trial.
Example:
The economic evaluation was conducted from the per-
spective of the UK NHS. Data gathered were the dur-
ation of the visit and the grade of recruitment staff. Staff
time was valued using annual salaries, including em-
ployer oncosts (UK statutory contributions to pensions
and national insurance), obtained from one centre, ad-
justed for number of weeks worked per year, number of
hours worked per week, and the proportion of time
Madurasinghe Trials  (2016) 17:27 Page 14 of 25
spent with patients. Comparisons between nurses and
urologists were performed using t tests and 95 % CIs for
differences between means. Planned sensitivity analyses
were undertaken to explore the impact of the number of
appointments and staff present [39].
Explanation:
Embedded trials assessing approaches to recruitment
are of particular interest to researchers looking to apply
these methods to their own trials. For researchers, not be-
ing able to recruit to target on time can delay the study
while increasing cost [1, 40]. In some trials, recruitment
issues may contribute to eventual stopping of the trial
mid-way [41]. Reports of recruitment interventions must
therefore strive to provide as much information as pos-
sible on any additional analyses done (e.g. the analyses of
gender differences in the paper by Man et al. [13], see
Additional file 1, Item 12b) for intended users, so that they
can make an informed decision. Recruitment cost is an
important aspect of any trial budget. Where possible, re-
ports on recruitment interventions should therefore in-
clude an economic evaluation as an integral part of their
analysis (e.g. Donovan et al. [39]). This may not necessar-
ily be a full health economic analysis. Further, we suggest
that if effects on retention are not evaluated as primary or
secondary outcome(s), trials of recruitment interventions
should consider including retention as a long-term out-
come. These could be classed as additional analyses.
Results: participant flow (a diagram is strongly
recommended)
Item 13a
Standard CONSORT 2010 item: for each group, the
numbers of participants who were randomly assigned,
received intended treatment, and were analysed for the
primary outcome.
Extension for embedded recruitment trial: for each group
in the embedded recruitment trial, the numbers of partici-
pants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome.
Example:
Figure 4 presents the participant flowchart for an em-
bedded trial where recruitment intervention was embed-
ded in two host trials [13].
Explanation:
Participant flow in an embedded recruitment trial will
usually not coincide with its host trial(s). In some instances,
the embedded trial could be included as an integral part of
the host participant flow chart. In others, the embedded
trial may assess the numbers randomised to the host trial(s)
as its primary outcome and therefore could be viewed as an
Healthlines CVD
Assessed as potentially 
eligible n=725
Healthlines Depression
Assessed as potentially 
eligible n=1482
Excluded 
by GP 
N=54
Excluded 
by GP 
N=118
Healthlines CVD
n=671 mailed invitation to 
the trial
Original n=333 Optimised n=338 
Healthlines Depression
n=1364 mailed invitation 
to the trial
Optimised n=682Original n=682
Positive response n=73
Negative response n=82
Positive response n=126
Negative response n=217
Positive response n=106
Negative response n=224
Positive response n=81
Negative response n=94
Embedded trial
Original or optimised patient 
information materials
Randomised n=27 Randomised n=43
Fig. 4 Recruitment flowchart
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appendix to the host trial(s) flow chart. The flow chart
should provide information on how many were allocated to
each group in embedded trial, whether all participants did
or did not receive the allocated treatment and, if known,
why some did not, or exclusions from analysis. In embed-
ded recruitment trials there are technically no losses to
follow-up since it will be known for each participant
approached whether they were recruited or not. Neverthe-
less, investigators may wish to distinguish between those
who refused and those who did not respond.
The exact layout and content of the flow chart is trial
dependent, and to a certain extent will depend on the
respective host trial(s) and characteristics of recruit-
ment interventions. For example, the information pre-
sented in the flow chart may include overall numbers
approached, accepted, did not respond, undelivered,
declined, recruited and randomly assigned, received
intended recruitment intervention and retained with
full follow-up as appropriate, and were included in pri-
mary outcome analysis of host trial(s). Examples of dif-
ferent layouts that could be used for presenting
embedded trials are provided (Figs. 4, 5 and 6).
Item 13b
Standard CONSORT 2010 item: for each group, losses and
exclusions after randomisation, together with reasons).
Extension for embedded recruitment trial: for each
group, losses and exclusions after randomisation to
the embedded recruitment trial, together with reasons.
Example:
Of the 1529 patients aged ≥65 years registered with
the practice, 273 (17.9 %) were excluded. See Fig. 7 for
details [35].
Explanation:
The intervention in an embedded recruitment trial is
usually short in nature and losses during the interven-
tion period are therefore unlikely. Exclusions may hap-
pen between randomisation and the intervention (e.g.
Harris et al. [35]).
Item 14a
Standard CONSORT 2010 item: dates defining the pe-
riods of recruitment and follow-up.
Extension for embedded recruitment trial: dates defin-
ing the periods of recruitment and follow-up for both
embedded recruitment trial and host trial(s).
Example:
The intervention study is investigating the effect of a
1-year moderate intensity exercise intervention on
serum levels of endogenous sex hormones in postmeno-
pausal women.
Recruitment began in January 1998 and finished in July
2000. Previous research suggests that different mailing
strategies can affect the response rate. Therefore, at the
beginning of the recruitment period, we conducted a pilot
study of four mailing strategies and used the results to de-
termine the mailing method for use during the remainder
of recruitment. The recruitment packets for the pilot
study were mailed 3 weeks apart in February and March
1998 [23].
Explanation:
It is important to note that the embedded recruitment
trial may not necessarily start nor will it necessarily con-
tinue for the duration of the host trial(s). Therefore, authors
should clearly report whether the embedded recruitment
trial lasted as long as the host trial, or was shorter.
Item 14b
Standard CONSORT 2010 item: why the trial ended or
was stopped.
Extension for embedded recruitment trial: why the
embedded recruitment trial ended or was stopped.
Example:
The present study was carried out within a rando-
mised clinical trial for patients with node-positive breast
cancer (AERO-B2000). The present study initially aimed
at studying the impact of all monitoring visits, i.e. initi-
ation, on-going and closeout visits on (1) patients’ re-
cruitment, (2) quantity of data spontaneously reported,
(3) quality of data, and (4) patients’ follow-up time.
The study started in March 2000 and was terminated
in March 2002, when the AERO group decided to redir-
ect on-site monitoring visits (which is the recruitment
intervention evaluated in this trial) to centres in which a
problem had been identified, either because they had
not sent any data to the coordination centre, or because
they lacked time and adequate administrative support to
complete the case report forms. This shift in monitoring
activities implied termination of the present study, with
most initiation visits completed as planned but only a
few on-site visits and no closeout visits [37].
Explanation:
Moher et al. [7] discussed the reasons for reporting
this item in detail.
Baseline data
Item 15
Standard CONSORT 2010 item: a table showing base-
line demographic and clinical characteristics for each
group.
Extension for embedded recruitment trial: if possible a
table showing baseline characteristics of each arm of the
embedded recruitment trial.
Example:
Table 2 shows an example where researchers were able
to collect baseline characteristics from participants
approached [42].
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Explanation:
In recruitment trials it is the participants approached
who should be included in the baseline table. It is not
always possible to know the number of eligible partici-
pants approached or their characteristics (illustrated in
Additional file 1, Item 15, example 2 [43]: in this trial
the focal point for the recruitment intervention was tele-
phone screening of participants for eligibility).
Numbers analysed
Item 16
Standard CONSORT 2010 item: for each group, num-
ber of participants (denominator) included in each
analysis and whether the analysis was by original
assigned groups.
Extension for embedded recruitment trial: for each
group in the embedded recruitment trial, number of
Fig. 5 Recruitment flowchart
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participants (denominator) included in each analysis and
whether the analysis was by original assigned groups.
Example:
A total of 2397 families were randomised, 1203 to
receive the questionnaire with the invitation to take
part and 1194 to receive the invitation without the
questionnaire. Four invitations were returned as not
known at that address and were excluded from the
analysis [44].
Explanation:
The number of participants in each intervention arm
is an essential element of RCT results. Failure to include
all participants may bias trial results [18]. Denominator
data for embedded trials tends to be poorly reported. It
is important to note that in embedded recruitment trials,
the denominator is usually the number of participants
who were initially approached. This is a larger number
than that used in power calculations for clinical out-
comes within individual host trial(s). In some recruitment
interventions (such as newspaper advertisements), however,
this number is impossible to know (e.g. Miller et al. [43],
see Additional file 1, Item 16: in this trial the numbers who
responded to media advertisements were included as the
denominator).
Outcomes and estimation
Item 17a
Standard CONSORT 2010 item: for each primary and
secondary outcome, results for each group, and the esti-
mated effect size and its precision (such as 95 % CI)
[50].
Total 
disclosure
Eligible for 
clinical trial
Eligible for 
consent study
Background 
information
Randomised 
consent procedure
Register only
Individual 
approach
Treatment 
randomised
Refused
Seek consent
Given
NoYes
Management as 
appropriate
Treatment 
A
Treatment 
B
Repeat questionnaire 
at 3 – 4 weeks
Questionnaire
Record of consent 
interview
Fig. 6 Recruitment flowchart
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Extension for embedded recruitment trial: for each
primary and secondary outcome, results for each group
in the embedded recruitment trial, and the estimated ef-
fect size and its precision (such as 95 % CI).
Example:
Telephone contact by the research nurse increased the
recruitment rate: contact 47.9 % (134/280), no contact
37.9 % (106/280) and difference 10.0 % (95 % CI 0.2–19.8)
(Table 3) [35].
Explanation:
Rationale for reporting this item is given in Moher et
al. [7].
Item 17b
Standard CONSORT 2010 item: for binary outcomes,
presentation of both absolute and relative effect sizes is
recommended
Fig. 7 CONSORT diagram showing the flow of participants through each stage of the randomised trial (enrolment, intervention allocation, follow-up
and data analysis)
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Extension for embedded recruitment trial: for binary
outcomes in the embedded recruitment trial, presentation
of both absolute and relative effect sizes is recommended.
Example:
Of the 180 people given information about the open
trial design, 134 (74.4 %) consented, compared with
233 (65.1 %) of 358 given information about the
blinded, placebo-controlled design (difference 9.4 %,
95 % CI 1.3–17.4 %; OR 1.56, 95 % CI 1.05–2.33). The
OR was not materially influenced by adjusting for age,
sex, type of fracture and time since fracture (OR 1.58,
95 % CI 1.06–2.36) [30].
Explanation:
An explanation for reporting this item is provided in
Moher et al. [7].
Ancillary analyses
Item 18
Standard CONSORT 2010 item: results of any other
analyses performed, including subgroup analyses and
adjusted analyses, distinguishing pre-specified from
exploratory
Extension for embedded recruitment trial: results of any
other analyses performed for the embedded recruitment
trial, including subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
Example:
Using e-mail did not improve recruitment (risk differ-
ence 50.7 %, 95 % CI 2.7–4.1 %).
Sending out postal invitations and reminders took ap-
proximately two working days longer (40 vs. 26 h) than
sending out e-mails. The total amount of time spent
sending out the invitations and reminders was 66 h, the
cost of which was estimated at approximately £1122 as-
suming mid-point grade 6 on the UK university pay
scale. Apart from staff time, the cost of sending out e-
mails was considered to be free to the WIME. The cost
of materials and postage for sending postal invitations
and reminders was estimated to be £1391. Our overall
response rate of 15 % for postal invitations meant
that the cost of sending out each round of reminders
was less than the cost of the initial invitation but not
dramatically so. We recruited 66 GPs from the initial
880 who received a postal invitation, meaning we sent
out 814 first reminders. We received 35 responses to
the first reminder and sent out 779 second reminders.
The cost per reminder round of about £669 is 91 %
of the £733 initial cost, which corresponds reasonably
well with the fact that we re-sent materials to 93 %
of GPs in the first reminder round and 89 % in the
second round. The total cost of the e-mail invitations
was £442 compared with £2071 for the postal invita-
tions, giving a cost per recruit of £3.20 for e-mail and
£15.69 for post. The total cost of sending the
vouchers was estimated to be £371 (14 h of staff time
costing £238 plus £133 printing and post). The cost
to the project of getting vouchers was their face value
plus some of ST’s time, estimated at around 4 h [11].
Explanation:
An example economic evaluation that authors may
consider performing is presented.
Table 3 Effect of interventions on recruitment into host trial [35]
Interventions Recruitment in
intervention
group
Recruitment in
control group
Difference in recruitment
intervention minus control
(95 % CI) adjusted for the
clustering effect of
household (395 households)
OR (95 % CI) for
recruitment into study
adjusted for clustering
effect of household
(395 households)
Telephone (groups 3 + 4 versus
control (groups 1 + 2)
134/280 (47.9 %) 106/280 (37.9 %) 10.0 % (0.2–19.8 %) 1.5 (1.0–2.3)
P = 0.046
Questionnaire (groups 2 + 4) versus
control (groups 1 + 3)
116/280 (41.4 %) 124/280 (44.3 %) −2.9 % (−12.7–7.0 %) 0.9 (0.6–1.3)
P = 0.570
Table 2 Characteristics of all participants (n = 703) [42]
Intervention Control
(n = 356) (n = 347)
Mean age 41.11 41.53
(SD = 10.9) (SD = 10.7)
Gender
Male 116 (32.6 %) 104 (30.0 %)
Female 240 (67.4 %) 243 (70.0 %)
Number of episodes of sick leave
One episode in the last 2 years 168 (47.2 %) 179 (51.6 %)
Two or more episodes in the last 2 years 188 (52.8 %) 168 (48.4 %)
Diagnosis
Mental health problems 163 (45.8 %) 160 (46.1 %)
Muscle-skeletal problems 154 (43.3 %) 147 (42.4 %)
Other diagnosis 39 (11.0 %) 40 (10.5 %)
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Harms
Item 19
Standard CONSORT 2010 item: all important harms or
unintended effects in each group (for specific guidance
see CONSORT for harms [45]).
Extension for embedded recruitment trial: all important
harms or unintended effects in each group for both the
embedded recruitment trial and host trial(s) (for specific
guidance see CONSORT for harms [45]).
Example:
We found that monetary incentives had a positive ef-
fect on adolescents’ response to a mailed survey on their
willingness to be contacted about a future smoking pre-
vention and cessation intervention. Although response
rates differed by group, use of monetary incentives did
not appear to strongly bias study recruitment either to-
ward or away from smokers, compared to no incentive,
nor did they appear to bias response in terms of age or
gender. However, monetary incentives did nothing to al-
leviate existing age and gender differences in response.
Although monetary incentives of the types employed
in this study were effective in improving response rates
to mail-based surveys of adolescents, with no adverse
impact on willingness to further participate in interven-
tion activities, monetary incentives are not a panacea.
The observed age and gender differences in response
suggest that, while manipulation of mailing strategies
and use of monetary incentives may yield relatively high
response rates, these techniques may not overcome dif-
ferential non-response by subgroups. Moreover, beyond
the initial survey response, the proportion of subjects
available for subsequent randomisation into intervention
study was still low, ranging from 29 % to 44 %, depend-
ing on incentive group. While we do not observe any
negative differentials in willingness to be subsequently
contacted, there was a fairly uniform drop-off across
groups, with roughly one third of subjects who com-
pleted the survey indicating that they would not partici-
pate further. We will not know the true effects of
incentives on actual study participation until follow-up,
2 years from baseline, since willingness to be contacted is
only a proxy for actual participation. It remains to be seen
whether those who agreed to contact and were randomised
to the smoking prevention and cessation intervention will
actually become engaged with the intervention activities,
and whether this engagement differs by the incentive group
at baseline. Finally, since the use of incentives may have
established an expectation of similar incentives accompany-
ing follow-up surveys, or otherwise altered a subject’s com-
mitment to participate in the intervention, it remains to be
seen whether there will be differential loss to follow-up be-
tween subjects who received incentives with rates at base-
line and those who did not [46].
Explanation:
Readers need information about the harms as well as
the benefits of interventions to make rational and
balanced decisions. The existence and nature of adverse
effects can have a major impact on whether a particular
intervention will be deemed acceptable and useful [7]. In
embedded recruitment trials, any harmful effects of em-
bedded interventions can directly affect the host trial(s).
Therefore, unintended effects in both embedded and
host trial(s) must be clearly reported.
Discussion: limitations
Item 20
Standard CONSORT 2010 item: trial limitations, address-
ing sources of potential bias, imprecision, and, if relevant,
multiplicity of analyses.
Extension for embedded recruitment trial: embedded re-
cruitment trial limitations, addressing sources of potential
bias, imprecision, and, if relevant, multiplicity of analyses.
Example:
The major limitation of the present study is that it was
terminated after 2 years, while patient recruitment was
still on-going, with most centres in the visited group
having been visited only once (initiation visit).
The study could not evaluate the impact of repeated
on-site visits on the outcomes of interest, in particular
on clinical outcomes [37].
Explanation:
The importance of reporting both pros and cons of
the study was discussed by Altman et al. [18] and
Moher et al. [7].
Generalisability
Item 21
Standard CONSORT 2010 item: generalisability (external
validity, applicability) of the trial findings.
Extension for embedded recruitment trial: generalis-
ability (external validity, applicability) of the embedded
recruitment trial findings.
Example:
Another drawback of this study was that more than
90 % of the participants were white women. Further
studies should substantiate the study results in men and
minority populations [26].
Explanation:
Rationale for discussing the generalisability of the trial find-
ing is provided by Altman et al. [18] and Moher et al. [7].
Interpretation
Item 22
Standard CONSORT 2010 item: interpretation consist-
ent with results, balancing benefits and harms, and con-
sidering other relevant evidence.
Extension for embedded recruitment trial: interpretation
consistent with results of the embedded recruitment trial,
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balancing benefits and harms, and considering other rele-
vant evidence.
Example:
The overall physical activity study recruitment rate was
43 % (240/560) and the questionnaire survey response rate
was 69 % (192/280). The latter compares well to other
physical activity surveys among older primary care pa-
tients (46 %, 57 %). Our physical activity study involved
participants wearing activity monitors and keeping activity
logs for 1 week, less commitment than an intervention
study, but more than a questionnaire survey; this is
reflected in our recruitment rate being higher than phys-
ical activity intervention studies in this age group.
We found that telephone contact with a research
nurse after receiving study information increased re-
cruitment. Researchers planning studies where recruit-
ment may be low are most likely to consider the extra
costs in terms of time and effort incurred by telephon-
ing, a valuable investment for improved recruitment. It
is important to recognise that such telephone contact
could be considered intrusive and an opportunity for
people to opt out should be given [35].
Explanation:
An important aspect of any trial reporting is providing
as much information as possible so that future studies
can benefit from its findings. Therefore, where possible,
interpretation of results should reflect a balanced view
of benefits considering the cost and time incurred,
possible mechanisms for observed differences, participant
acceptability, feasibility and implications for future studies.
Other information: registration
Item 23
Standard CONSORT 2010 item: registration number and
name of trial registry.
Extension for embedded recruitment trial: registration
number and name of trial registry (for all host trials and
embedded recruitment trial if available).
Explanation:
Moher et al. [7] provides a detailed discussion on why
this item should be reported. It is important to note that
embedded methodology trials such as embedded recruit-
ment trials may be registered as a sub-study of its host
trial. If so, that information should be clearly reported.
Protocol
Item 24
Standard CONSORT 2010 item: where the full trial
protocol can be accessed, if available.
Extension for embedded recruitment trial: where the
embedded recruitment trial protocol can be accessed, if
available.
Explanation:
Explanation for reporting this item is given by
Moher et al. [7].
Funding
Item 25
Standard CONSORT 2010 item: sources of funding and
other support (such as supply of drugs), role of funders.
Extension for embedded recruitment trial: for embedded
recruitment trial, sources of funding and other support,
role of funders and collaborators.
Explanation:
Supply details for new technologies or incentives used
for recruitment (e.g. apps, information sheets, monetary
incentives type, website addresses used as interventions)
should be stated here.
Discussion and conclusions
We have developed a revised checklist for reporting em-
bedded recruitment trials in line with the CONSORT
statement 2010. We recommend that authors should fol-
low the principles laid out in the CONSORT statement
2010 and report all items listed as essential. Authors
must pay special attention to specific recommendations
we have made, where reporting requirements for these
trials differ from CONSORT. The examples we have
provided are intended to assist authors to report their
own trials transparently. We recommend that trialists
consider the embedded recruitment trial as a separate
trial from its host trial(s), with all aspects of good trial
design, conduct and reporting adhered to.
We have followed a robust process endorsed in
EQUATOR (Enhancing the Quality and Transparency
of health Research) guidelines in developing our
reporting criteria, including consensus meetings and
piloting [10]. Limited resources and time within the
MRC START programme (of which our work was a
part) meant that we did not conduct a Delphi consen-
sus process, and our consensus meetings were each
over 1 day only. Nevertheless, we did seek consensus
from a wider range of participants.
The item checklist for embedded recruitment trials
does not include additional items, similar to CON-
SORT extensions for reporting specific types of RCTs,
which differ little from the CONSORT statement that
they were based on, e.g. CONSORT non-inferiority
[47], and CONSORT for pragmatic trials [48]. How-
ever, we did identify items that need to be considered
carefully and reported differently in embedded re-
cruitment trials. These include item 2a—scientific
background and explanation of rationale; 4a—eligibil-
ity criteria for participants; 4b—settings and locations
where the data were collected; 5—interventions;
7a—sample size; 11a–11b—blinding; 12b—additional
analyses; 13a—participant flow diagram; 14a—defining
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recruitment and follow-up periods; 15—baseline data
tables; 16—number of participants (denominator) in-
cluded in each analysis; 19—important harms or un-
intended effects; 23—trial registration; and
25—funding and other support. Items listed here
highlight the need for rigorous design and conduct of
embedded methodological trials to ensure unbiased
results. We believe these reporting guidelines (par-
ticularly the examples) provide a useful tool for those
designing embedded recruitment trials.
In developing these guidelines the primary focus was
embedded recruitment trials, mainly because the MRC
START research programme was initiated to improve
recruitment to clinical trials. However, we believe the
science underpinning embedded recruitment trials can
be extended to other embedded method trials and these
guidelines can be applied for those trials.
The primary goal of an embedded recruitment trial
may be to facilitate recruitment in the host trial or a spe-
cific patient group where recruitment was a particular
issue. However, to maximise benefits to the research
community, those carrying out embedded recruitment
trials should report them in a way which ensures re-
searchers can apply the findings appropriately. We hope
the guideline we have presented here will facilitate this
and will have a ripple effect on design and conduct of
embedded trials as a whole.
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